Could different treatment approaches in acromegaly influence life expectancy? A comparative study between Bulgaria and Campania (Italy)
- 1 August 2014
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 171 (2) , 263-273
Abstract
Background: Mortality in acromegaly strictly depends on optimal control of GH and IGF1 levels. Modern medical therapy with somatostatin analogs (SSAs) and GH receptor antagonists (GHRAs) is not available in many countries due to funding restrictions. This retrospective, comparative, cohort study investigated the impact of different treatment modalities on disease control (GH and IGF1) and mortality in acromegaly patients.Methods: Two cohorts of patients with acromegaly from Bulgaria (n=407) and Campania, Italy (n=220), were compared, and mortality rates were evaluated during a 10-year period (1999–2008).Results: The major difference in treatment approach between cohorts was the higher utilization of SSAs and GHRAs in Italy, leading to a decreased requirement for radiotherapy. Significantly more Italian than Bulgarian patients had achieved disease control (50.1 vs 39.1%, P=0.005) at the last follow-up. Compared with the general population, the Bulgarian cohort had a decreased life expectancy with a standardized mortality ratio (SMR) of 2.0 (95% CI 1.54–2.47) that was restored to normal in patients with disease control – SMR 1.25 (95% CI 0.68–1.81). Irradiated patients had a higher cerebrovascular mortality – SMR 7.15 (95% CI 2.92–11.37). Internal analysis revealed an independent role of age at diagnosis and last GH value on all-cause mortality and radiotherapy on cerebrovascular mortality. Normal survival rates were observed in the Italian cohort: SMR 0.66 (95% CI 0.27–1.36).Conclusions: Suboptimal biochemical control was associated with a higher mortality in the Bulgarian cohort. Modern treatment options that induce a strict biochemical control and reduce the necessity of radiotherapy might influence the life expectancy. Other factors, possibly management of comorbidities, could contribute to survival rates.Keywords
This publication has 36 references indexed in Scilit:
- Resistance to Somatostatin Analogs in AcromegalyEndocrine Reviews, 2010
- Prevalence of pituitary adenomas: a community‐based, cross‐sectional study in Banbury (Oxfordshire, UK)Clinical Endocrinology, 2010
- Guidelines for Acromegaly Management: An UpdateThe Journal of Clinical Endocrinology & Metabolism, 2009
- Impact of Somatostatin AnalogsVersusSurgery on Glucose Metabolism in Acromegaly: Results of a 5-Year Observational, Open, Prospective StudyThe Journal of Clinical Endocrinology & Metabolism, 2009
- A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegalyEuropean Journal of Endocrinology, 2008
- First-line therapy of acromegaly: A statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study GroupJournal of Endocrinological Investigation, 2006
- High Prevalence of Pituitary Adenomas: A Cross-Sectional Study in the Province of Liège, BelgiumThe Journal of Clinical Endocrinology & Metabolism, 2006
- Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and ManagementEndocrine Reviews, 2004
- Epidemiology and Long‐term Survival in Acromegaly: A Study of 166 Cases Diagnosed between 1955 and 1984Acta Medica Scandinavica, 1988
- EPIDEMIOLOGY OF ACROMEGALY IN THE NEWCASTLE REGIONClinical Endocrinology, 1980